IP Library › Granted Patent US 12,514,923
Granted Patent B2
US 12,514,923 · App. 18/103,194 · Granted Jan 6, 2026

Methods of inhibiting the T cell receptor by administering a monoclonal antibody that binds TRBV9

Inventors: Olga Vladimirovna Britanova (Moscow, RU); Mark Aleksandrovic Izraelson (Moscow, RU); Sergey Anatolievich Lukyanov (Moscow, RU)
A61K39/3955A61P1/00A61P35/00A61P35/02A61P37/06A61K2039/505C07K16/2809C07K2317/24C07K2317/56C07K2317/565C07K2317/73C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,923
App. No.
18/103,194
Granted
Jan 6, 2026
Kind
B2
Abstract

The invention relates to monoclonal antibodies which specifically bind to the TRBV9 family of human T-cell receptors. The invention also relates to a nucleic acid which codes for said antibody or for an antigen-binding fragment thereof, to an expression vector, to a method for producing the antibody, and to the use of said antibody for treating diseases or disorders associated with the family of human T-cell receptors. The invention is directed towards producing antibodies that can be used for eliminating T-cells carrying T-cell receptors of the TRBV9 family, in particular for treating ankylosing spondylitis, coeliac disease, and blood cancers, in the pathogenesis of which T-cell receptors of the TRBV9 family are involved.

Claims (41)

1 . A method of inhibiting the biological activity of T cell receptor, the beta chain of which relates to the TRBV9 (T Cell Receptor Beta Variable 9) family, by administering an effective amount of an antibody or antigen-binding fragment comprising:

1) a heavy chain variable domain comprising HCDR1, HCDR2 and HCDR3, where

the HCDR 1 comprises the amino acid sequence of SEQ ID NO: 1,

the HCDR 2 comprises the amino acid sequence of SEQ ID NO: 2,

the HCDR 3 comprises the amino acid sequence selected from the group of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6; and

2) a light chain variable domain comprising LCDR1, LCDR2 and LCDR3, where

the LCDR 1 comprises the amino acid sequence of SEQ ID NO: 7,

the LCDR 2 comprises the amino acid sequence of SEQ ID NO: 8, and

the LCDR 3 comprises the amino acid sequence of SEQ ID NO: 9.

2 . The method according to claim 1 , wherein the heavy chain variable domain of the antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 19.

3 . The method according to claim 2 , wherein the heavy chain variable domain of the antibody or antigen-binding fragment comprises an amino acid sequence selected from the group of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 19.

4 . The method according to claim 1 , wherein the light chain variable domain of the antibody or antigen-binding fragment comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 11.

5 . The method according to claim 4 , wherein the light chain variable domain of the antibody or antigen-binding fragment comprises the amino acid sequence of SEQ ID NO: 11.

6 . The method according to claim 1 , wherein the antibody or antigen-binding fragment comprises:

1) a heavy chain having an amino acid sequence that is at least 90% identical to a sequence selected from the group SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, and SEQ ID NO: 27; and

2) a light chain having an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO: 29.

7 . The method according to claim 6 , wherein the antibody or antigen-binding fragment comprises:

1) a heavy chain comprising an amino acid sequence selected from the group of SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, and SEQ ID NO: 27; and

2) a light chain comprising the amino acid sequence of SEQ ID NO: 29.

8 . The method according to claim 1 , wherein the antibody is a full-length IgG antibody.

9 . A method of treating a disease or disorder mediated by human T cell receptor carrying the TRBV9 (T Cell Receptor Beta Variable 9) family beta chain, comprising administering to a subject in need of such treatment an antibody or antigen-binding fragment comprising:

1) a heavy chain variable domain comprising HCDR1, HCDR2 and HCDR3, where

the HCDR 1 comprises the amino acid sequence of SEQ ID NO: 1,

the HCDR 2 comprises the amino acid sequence of SEQ ID NO: 2,

the HCDR 3 comprises the amino acid sequence selected from the group of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6; and

2) a light chain variable domain comprising LCDR1, LCDR2 and LCDR3, where

the LCDR 1 comprises the amino acid sequence of SEQ ID NO: 7,

the LCDR 2 comprises the amino acid sequence of SEQ ID NO: 8, and

the LCDR 3 comprises the amino acid sequence of SEQ ID NO: 9.

10 . The method of treating a disease or disorder according to claim 9 , wherein the disease or disorder is selected from the group of ankylosing spondylitis, celiac disease, T cell leukemia, and T cell lymphoma.

11 . The method according to claim 9 , wherein the heavy chain variable domain of the antibody or antigen-binding fragment administered to the subject comprises an amino acid sequence that is at least 90% identical to an amino acid sequence selected from the group of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 19.

12 . The method according to claim 11 , wherein the heavy chain variable domain of the antibody or antigen-binding fragment administered to the subject comprises an amino acid sequence selected from the group of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, and SEQ ID NO: 19.

13 . The method according to claim 9 , wherein the light chain variable domain of the antibody or antigen-binding fragment administered to the subject comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 11.

14 . The method according to claim 13 , wherein the light chain variable domain of the antibody or antigen-binding fragment administered to the subject comprises the amino acid sequence of SEQ ID NO: 11.

15 . The method according to claim 9 , wherein the antibody or antigen-binding fragment administered to the subject comprises:

1) a heavy chain having an amino acid sequence that is at least 90% identical to a sequence selected from the group SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, and SEQ ID NO: 27; and

2) a light chain having an amino acid sequence that is at least 90% identical to the sequence of SEQ ID NO: 29.

16 . The method according to claim 15 , wherein the antibody or antigen-binding fragment administered to the subject comprises:

1) a heavy chain comprising an amino acid sequence selected from the group of SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, and SEQ ID NO: 27; and

2) a light chain comprising the amino acid sequence of SEQ ID NO: 29.

17 . The method according to claim 9 , wherein the antibody is a full-length IgG antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2023
From: BRITANOVA, OLGA VLADIMIROVNA; IZRAELSON, MARK ALEKSANDROVIC; LUKYANOV, SERGEY ANATOLIEVICH
To: JOINT STOCK COMPANY "BIOCAD"
Reel/Frame 063544/0841 →
Priority Claims (1)
RU RU2017145662 · Dec 25, 2017 · national
Continuity (2)
Continuation 16957328
Related Publication 20230357396A1 · Nov 9, 2023
References Cited (51)
US 11597767B2 · Britanova · 2023 [cited by examiner]
US 12227572B2 · Britanova · 2025 [cited by examiner]
US 12297269B2 · Britanova · 2025 [cited by examiner]
CA 3127767A1 · 2020 [cited by applicant]
CA 3124800A1 · 2020 [cited by applicant]
CA 3124813A1 · 2020 [cited by applicant]
JP 2017169566A · 2017 [cited by applicant]
RU 2539032C2 · 2015 [cited by applicant]
WO 9006758A1 · 1990 [cited by applicant]
WO 9405801A1 · 1994 [cited by applicant]
WO 2010151416A1 · 2010 [cited by applicant]
WO 2017137453A1 · 2017 [cited by applicant]
WO 2017216324A1 · 2017 [cited by applicant]
Corresponding Canadian patent application No. 3,086,849 Office Action dated Feb. 22, 2024. [cited by applicant]
Corresponding Chinese patent application No. 201880090210.0 Office Action dated Nov. 10, 2023. [cited by applicant]
Corresponding Japanese patent application No. 2020-535637 Notice of allowance dated Jun. 9, 2023. [cited by applicant]
International application No. PCT/RU2018/050168 International Search Report and its translation dated May 7, 2019. [cited by applicant]
International application No. PCT/RU2018/050168 Written Opinion and its translation dated May 7, 2019. [cited by applicant]
International application No. PCT/RU2018/050168 International Preliminary Report on Patentability Chapter I dated Jun. 30, 2020. [cited by applicant]
Corresponding European patent application No. 18895626.2 extended European search report dated Jul. 29, 2021. [cited by applicant]
Corresponding Japanese patent application No. 2020-535637 Office Action dated Dec. 9, 2022 (English translations provided). [cited by applicant]
Toyabe S et al., Biclonal expansion of T cells infected with monoclonal Epstein-Barrvims (EBV) in a patient with chronic, active EBV infection. Clinical & Experimental Immunology, vol. 134, Is. 1, Oct. 2003, p. 92-97. [cited by applicant]
Zhijun Liu et al., Prevention of Type 1 Diabetes in the Rat With an Allele-Specific Anti-T-Cell Receptor Antibody. Diabetes, vol. 61, No. 5, May 19, 2012 (May 19, 2012), pp. 1160-1168. [cited by applicant]
Faham M. et al . . . , Discovery of T Cell Receptor B Motifs Specific to HLA-B27-Positive Ankylosing Spondylitis by Deep Repertoire Sequence Analysis. Arthritis & Rheumatology (Hoboken), vol. 69, No. 4, Mar. 29, 2017 (M… [cited by applicant]
Navid et al, The enigmatic role of HLA-B*27 in spondyloarthritis pathogenesis. Seminars in Immunopathology (2021). 43: 235-243. [cited by applicant]
Medina Frederic et al., Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis. Therapeutic Drug Monitoring, vol. 39, No. 4, Aug. 2017 (Aug. 2017), pp. 360-363. [cited by applicant]
Israelson MA et al., Testing of monoclonal antibodies against the T-cell receptor associated with ankylosing spondylitis. Preventive Medicine, No. (5)2018, Dec. 1, 2018 (Dec. 1, 2018), pp. 71-79. [cited by applicant]
Baeten D, et al, Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. Dec. 24, 2015;373(26):2534-2548. [cited by applicant]
Kuhn C. and Weiner L., Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy Jul. 2016;8(8):889-906. [cited by applicant]
Helling B. et al., A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunology and Cell Biology Apr. 2015;93(4):396-405. [cited by applicant]
Konig M. et al., Tregalizumab—A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol Jan. 25, 2016; 7:11. pp. 1-7. [cited by applicant]
Haroon N et al., The Impact of Tumor Necrosis Factor α Inhibitors on Radiographic Progression in Ankylosing Spondylitis. Arthritis Rheum. Oct. 2013;65(10):2645-2654. [cited by applicant]
Duarte J. et al., Modulation of IL-17 and Foxp3 Expression in the Prevention of Autoimmune Arthritis in Mice. PloS One May 10, 2010;5(5):e10558. [cited by applicant]
Marie-Paule Lefranc, IMGT, the international ImMunoGeneTics database. Nucleic Acids Research, vol. 29, Issue 1, Jan. 1, 2001, pp. 207-209. [cited by applicant]
Petersen J et al., Determinants of Gliadin-Specific T Cell Selection in Celiac Disease. J Immunol. 2015; 194(12): 6112-22. [cited by applicant]
Brennan et al., Heterogeneity of T cell receptor idiotypes in rheumatoid arthritis . . . Clin Exp Immunol. Sep. 1988; 73(3):417-423. [cited by applicant]
Taylor L.D. et al. A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins. Nucleic Acids Research, vol. 20, Issue 23, Dec. 11, 1992, pp. 6287-6295. [cited by applicant]
Huston et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Holliger P et al. “Diabodies”: small bivalent and bispecific antibody fragments. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448. [cited by applicant]
Poljak R.J. et al. Production and structure of diabodies. (1994) Structure 2:1121-1123. [cited by applicant]
Kipriyanov S.M. et al. Single-chain antibody streptavidin fusions: Tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen. (1995) Human Antibodies and Hybridomas 6:93-101. [cited by applicant]
Colicelli et al., A temperature-sensitive mutation constructed by “linker insertion” mutagenesis. Mol. Gen. Genet. (1985) 199:537-539. [cited by applicant]
Olga V. Britanova et al., Dynamics of Individual T Cell Repertoires: From Cord Blood to Centenarians. J Immunol, 2016, 196(12) 5005-5013. [cited by applicant]
Van der Heijde D et al., 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases. Jun. 2011;70(6):905-908. [cited by applicant]
Turner SJ et al., Structural determinants of T-cell receptor bias in immunity. Nature Reviews Immunology 2006, V.6, 883-894. [cited by applicant]
Ward et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Bird et al. Single-chain antigen-binding proteins. (1988) Science 242:423-426. [cited by applicant]
Kipriyanov S.M. et al. Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: Production of bivalent and biotinylated miniantibodies. (1994) Mol. Immunol., 31:1047-1058. [cited by applicant]
Barany, Single-stranded hexameric linkers: a system for in-phase insertion mutagenesis and protein engineering. Gene (1985) 37: 111-123. [cited by applicant]
Yasuto Akiyama et al., Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. International Journal of Oncology (2008), vol. 33, Issue 3, Pub… [cited by applicant]
Corresponding European application No. 18895626.2 examination report dated Jan. 27, 2025. [cited by applicant]